🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

FIVE at FIVE AU: ASX has slow day; speculation still rife about Trump's next term

Published 11/11/2024, 04:04 pm
Updated 11/11/2024, 04:30 pm
© Reuters.  FIVE at FIVE AU: ASX has slow day; speculation still rife about Trump's next term
US500
-
DOW
-
AXAT
-
BTC/USD
-

Australian shares tacked lower today, falling 36.20 points or 0.44% to 8,258.90, despite crossing above their 20-day moving average.

The worst-performing stocks were Champion Iron Ltd and Iluka Resources Ltd, down 10.88% and 6.95% respectively.

Over the last five days, the index has gained 1.73% and is currently 1.50% off its 52-week high.

Information Technology, up 1.43%, and Real Estate, up 1.20%, led the pack this afternoon, in what was otherwise a slower day.

Dragging the bourse was Materials, the biggest loser, dropping 2.76%, while Consumer Staples took a 1.78% hit.

Small cap movers

Polymetals Resources Ltd (ASX:POL) continued its recent climb with shares hitting a new record of $0.91, an increase of 12.35% on Friday's close.

Other increases among the small caps came for Nexus Minerals Ltd (ASX:NXM), which was up as much as 27.8% to $0.069, Altech Batteries Ltd (ASX:ATC, OTC:ALTHF) was 20% higher to $0.078, Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) increased 17.08% to $0.048 and Globe Metals and Mining was up 13.51% to $0.042.

Jindalee Lithium Ltd (ASX:JLL, OTCQX:JNDAF) rose by 13.21% to $0.30, European Lithium Ltd (ASX:ASX:EUR, OTCQB:EULIF) reached $0.026, an increase of 8.33% on the last close, Orthocell Ltd (ASX:OCC, OTC:ORHHF) lifted by 7.82% to $0.69, Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF) increased 5.56% to $0.57 and Far East Gold Ltd (ASX:FEG, OTC:FEGDF) was up by 5.41% to $0.195.

What will second Trump term mean?

Speculation about what the second Trump term means for the markets flooded the zone today, as analysts continued to try to read the tea leaves.

“The bull market is on a tear with markets appearing to gain fresh legs for another run,” moomoo Australia’s Jessica Amir said.

“US stocks closed off their best week of the year on bets Trump will bolster US businesses, reduce taxes and regulation.

“And it’s at a time when US consumer sentiment rose to its highest in seven months with Americans optimistic about personal incomes strengthening.

“The S&P 500 rose 4.7% last week, closing at its 50th record high. The Dow Jones topped 44,000 for the first time after welcoming Nvidia to the top 30 index, with its US$3.6 trillion valuation (meaning it's twice as large as Australia’s entire sharemarket).

“The risk-on sentiment flowed into other markets. Bitcoin smashed US$80,000 for the first time as traders bet Trump will promote wide-scale Bitcoin adoption.

“The US dollar rose to four-month high territory, pushing down commodity prices, with aluminium, gold, iron ore, copper, silver, oil, coffee and sugar all falling more than 2% in sync.

“Today, the Australian share market is expected to have a negative day of trade and fall 0.35% to 8281 if you go by the futures.

“Australia’s market is vulnerable for a bumpy course ahead: expect a bout of profit-taking and de-risking for a couple key reasons.

“Firstly, traders will be questioning the strength of the US dollar, and how long it could remain elevated in anticipation of tariffs and Trump’s policies being announced.

“The higher USD is putting a great deal of pressure on commodity prices and stocks. And it’s at a time when traders are disappointed with China’s latest economic stimulus packages.

“So you could expect Aussies to rotate out of positions in Australia’s sharemarket and back momentum and top up positions in US stocks. Speaking of, US stocks are now up 72% in their two-year-old bull market.

“And the thinking is, that if history repeats, markets could run up 100% from here for the next two years. However, Trump’s administration and policies could up that ante.”

The five at five

Orthocell prepares for Remplir™ commercialisation in US with two executive appointments

Orthocell Ltd (ASX:OCC, OTC:ORHHF) is gearing up to launch its nerve repair product Remplir™ to the US market, with the final regulatory approval from the US Federal Drug Administration (FDA) expected in the first quarter of 2025.

Read more

Lindian Resources secures 10-year lease and royalty stream from Woula Bauxite Project in Guinea

Lindian Resources Ltd (ASX:LIN, OTC:LINIF) has signed binding agreements with Guinea-based Enterprise Generale d’Entretien & Construction and Lancinet Dabo, granting a 10-year lease and operational rights over the Woula Bauxite Project in Guinea, West Africa, providing a passive annual royalty stream.

Read more

Maximus Resources enhances lithium potential at Lefroy JV

Maximus Resources Ltd (ASX:MXR, OTC:MXRRF) has further validated its exploration methods and enhanced the critical minerals potential of the KOMIR Lefroy Lithium Joint Venture near Kambalda in Western Australia with high-grade results from the Bird Rock and Kandui prospects.

Read more

Riversgold awaits Northern Zone drilling results in strong gold price environment

Riversgold Ltd (ASX:RGL) has completed its latest round of aircore drilling as the company continues to expand the gold mineralised footprint at the Northern Zone Intrusive Hosted Gold Project, 25 kilometres from the Kalgoorlie Super Pit in Western Australia.

Read more

International Graphite secures second mining lease; unlocks full Springdale Graphite Project resource

A second mining lease for the Springdale Graphite Project has unlocked the second-largest graphite deposit in Australia for International Graphite Ltd, offering unfettered access to the majority of the mineral resource.

Read more

On your six

iseek acquisition paves way for HMC Capital’s A$4 billion ASX listing for DigiCo REIT

HMC Capital Ltd is moving swiftly to secure a $4 billion data centre fund listing on the ASX by next month, following its acquisition of the iseek co-location data centre platform for A$400 million which represents 19x CY25 forecast EBITDA.

Read more

The one to watch

Imugene expands CAR T-Cell and Oncolytic Virotherapy trials in Australia and the US

Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong joins Proactive’s Tylah Tully to provide a company update, including launching the first Australian site for the Phase 1b clinical trial of its azer-cel (azercabtagene zapreleucel) allogeneic CAR T-cell therapy.

Watch

Read more on Proactive Investors AU

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.